An Additional Mechanism of Action of Abciximab: Dispersal of Newly Formed Platelet Aggregates

Stanley J. Marciniak Jr.; Mary A. Mascelli; Mark I. Furman; Alan D. Michelson; Joseph A. Jakubowski; Robert E. Jordan; Peter J Marchese; Andrew L. Frelinger

doi:10.1055/s-0037-1613127

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2002; 87(06): 1020-1025
DOI: 10.1055/s-0037-1613127

Review Article

Schattauer GmbH

An Additional Mechanism of Action of Abciximab: Dispersal of Newly Formed Platelet Aggregates

Authors

Stanley J. Marciniak Jr.

¹Centocor, Malvern, PA
Mary A. Mascelli

¹Centocor, Malvern, PA
Mark I. Furman

²Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA
Alan D. Michelson

²Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA
Joseph A. Jakubowski

³Eli Lilly Inc, Indianapolis, IN, USA
Robert E. Jordan

¹Centocor, Malvern, PA
Peter J Marchese

²Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA
Andrew L. Frelinger

²Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA

Abstract

Summary

Background

The ability of abciximab to prevent fibrinogen binding to activated platelets indicates it may also promote dissolution of platelet-rich thrombi. The present study examined the capacity of abciximab to reverse platelet aggregation in vitro.

Methods and Results

Experiments were performed on blood from healthy non-medicated donors. Platelet aggregate formation and disaggregation were monitored turbidimetrically. Platelet-bound fibrinogen was measured by flow cytometry. For disaggregation studies, platelets were first stimulated with either ADP or the 11-mer thrombin receptor activating peptide (TRAP), then varying amounts of abciximab were added at periodic intervals after agonist addition. Platelet disaggregation was detected by comparing the extent of light transmittance at 4 min after addition of either abciximab or saline to PRP. ATP release was simultaneously monitored by chemi-luminescence. When added 1 min after low concentrations of ADP, abciximab rapidly (<1 min) dispersed platelet aggregates in a dose-dependent manner, with complete disaggregation observed with 6.25 µg/mL of the β₃ antagonist. In contrast, equivalent concentrations of abciximab did not induce appreciable disaggregation to platelets stimulated with TRAP (10 µM). Platelet counts of samples that had undergone complete disaggregation, as assessed by aggregometry, were equivalent to baseline, indicating dispersal of aggregates to single cells. Concentrations of abciximab that produced complete disaggregation induced partial displacement of platelet-bound fibrinogen (52 ± 8% inhibition of fibrinogen binding at 12.5 µg/ml abciximab). The disaggregation effectiveness of abciximab decreased as the time between ADP and subsequent abciximab addition widened, and as the amount of both dense granule release and agonist stimulation increased. However, pre-treatment of platelets with acetylsalicylic acid (ASA) did not potentiate platelet disaggregation induced by abciximab.

Conclusions

These data indicate that abciximab facilitates the dispersal of newly formed platelet aggregates in vitro, by partially displacing fibrinogen from activated GPIIb/IIIa receptors. In vivo, abciximab may destabilize coronary thrombi by preventing aggregate formation and dispersing mural thrombi.

Keywords

GPIIb/IIIa - abciximab - platelet aggregation - disaggregation

Full Text

References

References
1 Haerem JW. Platelet aggregates in intra myocardial vessels of patients dying suddenly and unexpectedly from coronary artery disease. Atherosclerosis 1972; 15: 199-213.
2 Haerem JW. Mural platelet micro-thrombi and major acute lesions of main epicardial arteries in sudden cardiac death. Atherosclerosis 1974; 19: 529-41.
3 Falk E. Unstable angina with fatal outcome. Dynamic coronary thrombosis leading to infarct and death. Circulation 1985; 71: 418-27.
4 Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intra myocardial platelet aggregation in patients with unstable angina suffering from sudden ischemic cardiac death. Circulation 1986; 73: 418-27.
5 Jordan RE, Wagner CA, Mascelli MA, Treacy G, Nedelman MA, Woody JN, Weisman HF, Coller BS. Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa. In Horton MA. (ed). Adhesion Receptors as Therapeutic Targets. Boca Raton, FL: CRC Press; 1996: 327-55.
6 Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and α_vβ₃ integrins. Circulation 1998; 98: 1085-91.
7 Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of 1024 chimeric glycoprotein IIb/IIIa integrin anti-platelet antibody Fab 7E3 in high risk coronary angioplasty. Circulation 1994; 90 (04) 1757-64.
8 Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade. Circulation 1998; 97: 1680-8.
9 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Eng J Med 1994; 330: 956-61.
10 The EPILOG Investigators: Platelet glycoprotein IIB/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Eng J Med 1997; 336: 1689-96.
11 The CAPTURE Investigators: Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997; 349: 1429-35.
12 EPISTENT Investigators. Randomised placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92.
13 Gold HK, Coller B, Yasuda T, Saito T, Fallon J, Guerrereo J, Leinbach RC, Ziskind A, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal anti-platelet GPIIb/IIIa antibody in a dog model. Circulation 1988; 77 (03) 670-7.
14 Kohmura C, Gold HK, Yasuda T, Holt R, Nedelman MA, Guerrereo JL, Weisman HF, Collen D. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterio Thromb 1993; 13: 1837-42.
15 Lu HR, Gold HK, Wu Z, De Cock F, Jang IK, Pauwels P, Collen D. Acceleration and persistence of recombinant tissue plasminogen activator induced arterial erosion graft recanalization with a single bolus injection of F(ab’)2 fragments of the anti-GPIIb/IIIa antibody 7E3. Coronary Artery Disease 1991; 02: 1039-46.
16 Jordan RE, Nakada MT, Mascelli MA, Mace KF, Nedelman MA. Abciximab affords early and sustained reperfusion by reduced-dose reteplase in a primate model of severe arterial injury. Circulation. 1998 98. Suppl I-526 abstract.
17 Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, Leihnbach RC. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Circulation 1997; 95: 1755-9.
18 Vu T-KH, Wheaton VI, Hung DT. Domains specifying thrombin receptor interactions. Nature 1991; 353: 647-77.
19 Ingerman CM, Smith JB, Silver MJ. Direct measurement of platelet secretion in whole blood. Thromb Res 1979; 16: 335-44.
20 Gralnick HR, Williams SB, McKeown L. et al. Endogenous platelet fibrinogen: its modulation after surface expression is related to size-selective access to and conformational changes in the bound fibrinogen. Br J Haematol 1992; 80: 347-57.
21 Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, Valeri CR. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proceedings of the National Academy of Sciences, USA 1996; 93: 11877-82.
22 Wencel-Drake JD, Boudignon-Proudhon C, Dieter MG, Criss AB, Parise LV. Internalization of bound fibrinogen modulates platelet aggregation. Blood 1996; 87: 602-12.
23 Peerschke EIB. Reversible and irreversible binding of fibrinogen to platelets. Platelets. 1997 08. 311-7. (review article).
24 Bennet JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64: 1391-401.
25 Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest 1996; 98 (03) 863-74.
26 Cox AD, Devine DV. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood 1994; 83: 1006-16.
27 Reed GL, Houng AK. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Circulation 1999; 99: 299-304.
28 Cohen I, Berk DL, White JG. The effect of peptides and monoclonal antibodies that bind to platelet glycoprotein IIb/IIIa complex on the development of clot tension. Blood 1989; 73: 1880-7.
29 Hantgan RR, Moussa SA. Inhibition of platelet-mediated clot retraction by integrin antagonists. Thromb Res 1998; 89: 271-9.
30 Collet JP, Mishal Z, Soria J, Soria C, Thomas D, Montalescot G. Disaggregation of in vitro platelet-rich clots by abciximab increases fibrinogen exposure and promotes fibrinolysis. J Arth Vasc Biol 2001; 21: 142-8.